<DOC>
	<DOCNO>NCT02150564</DOCNO>
	<brief_summary>Phase 3 randomize open label trial evaluate 3 D navigable ultrasound ( SonoWand ) improve extent resection intra-axial brain tumor . All patient undergo resective surgery . In experimental arm , navigable 3 D ultrasound use . In standard arm , navigation use . This study help assess usefulness sononavigation improve radicality resection malignant glioma also access accuracy SonoWand predict residue ( histopathological correlation ) .</brief_summary>
	<brief_title>3D Ultra Sound Resection Brain Tumors</brief_title>
	<detailed_description>Routine presurgical evaluation patient conduct . The preoperative use steroid , antiepileptic medication would per standard procedure would document . In addition detail MRI evaluation perform ( include contrast enhance MRI study , diffusion MRI , perfusion MR , MR spectroscopy , dynamic-contrast-enhanced MRI permeability study , well functional MRI , tractography require ) 1 week prior date surgery . Navigation specific MR sequence would perform patient ( arm ) .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>1 . All radiologicallysuspected , previously untreated , supratentorial malignant glioma consider debulking surgery . 2 . Adults ( 18 year ) 3 . Eligible surgical therapy ( craniotomy stereotactic biopsy ) 4 . Resectability : A lesion would consider `` resectable '' surgeon feel radiologically image lesion remove ( reasonable certainty ) . Only deem resectable lesion include 1 . Unfit GA 2 . Unwilling study 3 . Unresectable lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Malignant glioma</keyword>
	<keyword>Sono RCT</keyword>
</DOC>